Clinical trial
A Phase I Study to Evaluate Drug-Drug Interaction of TQB3909 Tablets
NCT06165822 is registered in ClinicalTrials.gov with Chia Tai Tianqing Pharmaceutical Group Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Study to Evaluate Drug-Drug Interaction of TQB3909 Tablets
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- December 31, 2023
- Completion date
- March 31, 2024
- Enrollment
- 40 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
advanced malignant neoplasm